| Current Medical Articles |
|---|
 |
IndustryWeek
March 17, 2010 |
First Up - The Audacity of Hopelessness Do our political leaders have the resolve to steer us from an unsustainable path?   |
The Motley Fool
March 17, 2010
Brian Orelli |
An Aspiring Blockbuster Novartis gets some bad clinical-trial news on its blood pressure medication. |
The Motley Fool
March 16, 2010
Brian Orelli |
How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind. |
The Motley Fool
March 16, 2010
Brian Orelli |
No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move |
Chemistry World
March 15, 2010
Matt Wilkinson |
An agile future Nick Roelofs, president of Agilent Technology's life sciences group, discusses how the company is planning to ride the waves of the economic recovery. |
The Motley Fool
March 15, 2010
Brian Orelli |
Clinical Outcomes? Who Needs 'Em. Abbott's TriCor looks good on lab tests, but that's about all. |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
March 15, 2010
Brian Orelli |
Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison. |
BusinessWeek
March 11, 2010
Margaret Cronin Fisk et al. |
Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation. |
BusinessWeek
March 11, 2010
Ellen Gibson |
The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL. |
BusinessWeek
March 11, 2010 |
Four Ways to Raise HDL Four different routes to raising good cholesterol. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
March 11, 2010
Brian Orelli |
FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope. |
The Motley Fool
March 10, 2010
Brian Orelli |
Up 160% With Room to Run You've got to love biotech and InterMune. |
The Motley Fool
March 10, 2010
Brian Orelli |
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. |
The Motley Fool
March 10, 2010
Jennifer Schonberger |
A Key Representative Weighs In on Financial Reform and Health Care Paul Kanjorski, D-Pa, talks about what needs to change and what needs to get done on Capitol Hill. |
The Motley Fool
March 9, 2010
Brian Orelli |
Are Billions of Dollars in Revenue at Risk? Vaccine makers' lawsuit protection is called into question. |
The Motley Fool
March 9, 2010
Brian Orelli |
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. |
The Motley Fool
March 8, 2010
Brian Orelli |
Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
March 5, 2010
Brian Orelli |
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. |
BusinessWeek
March 4, 2010
Amanda Bennett |
Lessons of a $618,616 Death Two years after her husband's death, the author's cover story examines the costs of keeping one man alive to fight in the face of a dismal prognosis. |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
March 3, 2010
Brian Orelli |
Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
Inc.
March 1, 2010
Kasey Wehrum |
The Business of Mission County Hospital A look at the companies that supply the California hospital with virtual records, equipment repair, and laundry services |
InternetNews
March 1, 2010 |
Major Tech Firms Back Online Health Care Cisco, Dell, Google, IBM and Microsoft all make news at the major health care show. |
Chemistry World
February 26, 2010
Sarah Houlton |
Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain. |
Chemistry World
February 18, 2010
Matt Wilkinson |
Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut. |
Chemistry World
February 4, 2010
Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |
Philanthropy
January 1, 2010
Adam Keiper |
Breakthrough Medical research is dominated by government and corporate funding. How can philanthropic dollars find a distinctive niche? |
| There are 6399 old articles available for this category. |
